(1S,5S)-3-oxabicyclo[3.1.0]hexane-1-carboxylic acid | 1427158-38-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: (1S,5S)-3-oxabicyclo[3.1.0]hexane-1-carboxylic acid
• CAS: 1427158-38-0
• 化学式: C₆H₈O₃
• 分子量: 128.128
• InChiKey: KXQPXWJVQITPAZ-INEUFUBQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (1S,5S)-3-oxabicyclo[3.1.0]hexane-1-carboxylic acid 在 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 9.0h， 生成
  参考文献：
  名称：

  Discovery of benzo[d]imidazo[5,1-b]thiazole as a new class of phosphodiesterase 10A inhibitors

  摘要：

  The design, synthesis and structure activity relationship studies of a series of compounds from benzo[d]imidazo[5,1-b]thiazole scaffold as phosphodiesterase 10A (PDE10A) inhibitors are discussed. Several potent analogs with heteroaromatic substitutions (9a-d) were identified. The anticipated binding mode of these analogs was confirmed by performing the in silico docking experiments. Later, the heteroaromatics were substituted with saturated heteroalkyl groups which provided a tool compound 9e with excellent PDE10A activity, PDE selectivity, CNS penetrability and with favorable pharmacokinetic profile in rats. Furthermore, the compound 9e was shown to be efficacious in the MK-801 induced psychosis model and in the CAR model of psychosis. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.10.027
• 作为产物：
  描述：

  (1R,5S)-ethyl 2-oxo-3-oxabicyclo[3.1.0]hexane-1-carboxylate 在 sodium tetrahydroborate 、 对甲苯磺酸 、 lithium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 水 、 甲苯 为溶剂， 反应 7.0h， 生成 (1S,5S)-3-oxabicyclo[3.1.0]hexane-1-carboxylic acid
  参考文献：
  名称：

  [EN] PHTALAZINONE DERIVATIVES AS MPEGS -1 INHIBITORS
  [FR] DÉRIVÉS DE PHTALAZINONE EN TANT QU'INHIBITEURS DE MPGES-1

  摘要：

  本专利申请涉及公式(I)的双环化合物或其药用盐，作为mPGES-1抑制剂。这些化合物是微粒体前列腺素E合成酶-1（mPGES-1）酶的抑制剂，因此在治疗多种疾病或情况引起的疼痛和/或炎症方面非常有用，如哮喘、骨关节炎、类风湿性关节炎、急性或慢性疼痛和神经退行性疾病。

  公开号：

  WO2013072825A1

文献信息

• [EN] SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS mPGES-1 INHIBITORS<br/>[FR] COMPOSÉS À BASE D'HÉTÉROARYLE BICYCLIQUE SUBSTITUÉ CAPABLES D'INHIBER MPGES-1
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2013038308A1

  公开（公告）日：2013-03-21

  The present invention relates to bicyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (m PGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthama, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases. (I)

  本发明涉及公式（I）的双环化合物或其药用盐，作为mPGES-1抑制剂。这些化合物是微粒体前列腺素E合成酶-1（mPGES-1）酶的抑制剂，因此在治疗多种疾病或症状引起的疼痛和/或炎症方面具有用处，如哮喘、骨关节炎、类风湿关节炎、急性或慢性疼痛和神经退行性疾病。
• [EN] PHTALAZINONE DERIVATIVES AS MPEGS -1 INHIBITORS<br/>[FR] DÉRIVÉS DE PHTALAZINONE EN TANT QU'INHIBITEURS DE MPGES-1
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2013072825A1

  公开（公告）日：2013-05-23

  The present patent application is directed to bicyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (m PGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

  本专利申请涉及公式(I)的双环化合物或其药用盐，作为mPGES-1抑制剂。这些化合物是微粒体前列腺素E合成酶-1（mPGES-1）酶的抑制剂，因此在治疗多种疾病或情况引起的疼痛和/或炎症方面非常有用，如哮喘、骨关节炎、类风湿性关节炎、急性或慢性疼痛和神经退行性疾病。
• [EN] EGFR INHIBITORS<br/>[FR] INHIBITEURS D'EGFR
  申请人：[en]BLUEPRINT MEDICINES CORPORATION

  公开号：WO2023196283A1

  公开（公告）日：2023-10-12

  The present disclosure provides a compound represented by structural formula (A) or (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
• Discovery of benzo[d]imidazo[5,1-b]thiazole as a new class of phosphodiesterase 10A inhibitors
  作者：Abhisek Banerjee、Lakshminarayana Narayana、Firoj A. Raje、Dnyandeo V. Pisal、Pradip A. Kadam、Srinivas Gullapalli、Hemant Kumar、Sandeep V. More、Malini Bajpai、Ramachandra Rao Sangana、Satyawan Jadhav、Girish S. Gudi、Neelima Khairatkar-Joshi、Ravi R.T. Merugu、Sreedhara R. Voleti、Laxmikant A. Gharat

  DOI：10.1016/j.bmcl.2013.10.027

  日期：2013.12

  The design, synthesis and structure activity relationship studies of a series of compounds from benzo[d]imidazo[5,1-b]thiazole scaffold as phosphodiesterase 10A (PDE10A) inhibitors are discussed. Several potent analogs with heteroaromatic substitutions (9a-d) were identified. The anticipated binding mode of these analogs was confirmed by performing the in silico docking experiments. Later, the heteroaromatics were substituted with saturated heteroalkyl groups which provided a tool compound 9e with excellent PDE10A activity, PDE selectivity, CNS penetrability and with favorable pharmacokinetic profile in rats. Furthermore, the compound 9e was shown to be efficacious in the MK-801 induced psychosis model and in the CAR model of psychosis. (C) 2013 Elsevier Ltd. All rights reserved.